Renin-angiotensin-aldosterone system inhibitor use improves clinical outcomes in patients with metabolic dysfunction-associated steatotic liver diseases: Target trial emulation using real-world data

Hepatology

Longitudinal response to standard of care in pediatric metabolic dysfunction-associated steatotic liver disease: Rates of improvement and worsening, and factors associated with outcomes

Hepatology

Newton KP, Jayasekera D, Blackford AL, Behling C, Wilson LA, Fishbein MH, Molleston JP, Xanthakos SA, Vos MB, Schwimmer JB, NASH CRN

doi: 10.1097/HEP.0000000000001216

Hepatology

Prevalence of metabolic dysfunction-associated steatotic liver disease and fibrosis defined by liver elastography in the United States using National Health and Nutrition examination survey 2017-march 2020 and august 2021-august 2023 data

Hepatology

Unalp-Arida A, Ruhl CE

doi: 10.1097/HEP.0000000000001211

Further Publications

Neighborhood social determinants of health are associated with metabolic dysfunction-associated steatotic liver disease outcomes

Clin Gastroenterol Hepatol

Faulkner CS, Aboona MB, Surendra L, Rangan P, Ng CH, Huang DQ, Muthiah M, Kim D, Fallon MB, Noureddin M, Chen VL, Kardashian A, Wijarnpreecha K

doi: 10.1016/j.cgh.2024.10.019

Hepatology

Metabolic dysfunction-associated steatotic liver disease, metabolic alcohol-related liver disease, and incident dementia: a nationwide cohort study : MASLD, MetALD, and dementia risk

BMC Gastroenterol

Shin WY, Kang ES, Oh YH, Sha M, Xia Q, Jeong S, Cho Y

doi: 10.1186/s12876-025-03814-1

HepatologyFurther Publications

GLP-1 Receptor Agonists and Risk for Cirrhosis and Related Complications in Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease

JAMA Intern Med

Kanwal F, Kramer JR, Li L, Yang YX, Cao Y, Yu X, Samuel R, Ali B, Desiderio R, Cholankeril G, Bajaj M, El-Serag HB, Asch SM

doi: 10.1001/jamainternmed.2024.4661

Hepatology

From "Burnt-Out" to "Burning-Out": Capturing Liver Fat Loss in Patients with Advanced Metabolic Dysfunction-Associated Steatotic Liver Disease from A Dynamic Perspective

Gastroenterology

Liu WY, Huang S, Ji H, Kim SU, Cheuk-Fung Yip T, Lai-Hung Wong G, Petta S, Tsochatzis E, Nakajima A, Bugianesi E, George Goh BB, Chan WK, Romero-Gomez M, Sanyal AJ, Boursier J, Hagström H, Calleja JL, de Lédinghen V, Newsome PN, Fan JG, Lai M, Castéra L, Lee HW, Pennisi G, Yoneda M, Armandi A, Kim-Jun Teh K, Gallego-Durán R, Asgharpour A, de Saint-Loup M, Shang Y, Llop E, Fournier C, Mahgoub S, Lara-Romero C, Canivet CM, Sau-Wai Chan M, Lin H, Chen LL, Targher G, Byrne CD, Du M, Wai-Sun Wong V, Zheng MH, VCTE-Prognosis Study Group

doi: 10.1053/j.gastro.2025.02.034

Hepatology

Optimal population screening strategies for liver fibrosis associated with metabolic dysfunction-associated steatotic liver disease

Am J Gastroenterol

Kim WR, Mannalithara A, Charu V, Chung N, Kwong A, Kwo PY, Torok NJ, Asch SM, Kim SH

doi: 10.14309/ajg.0000000000003268

Further Publications

Cardiovascular risk assessment tools are insufficient for patients with metabolic dysfunction associated steatotic liver disease

Am J Gastroenterol

Barritt AS 4th, Tapper EB, Newsome PN, Gazis D, Morris H, Mospan AR, Perez AD, Kim Y, Neuschwander-Tetri BA, Loomba R, Sanyal A, TARGET-NASH Investigators

doi: 10.14309/ajg.0000000000003595

Hepatology

The clinical value of serum sirtuin-1 concentration in the diagnosis of metabolic dysfunction-associated steatotic liver disease

BMC Gastroenterol

Amirkhizi F, Taghizadeh M, Khalese-Ranjbar B, Hamedi-Shahraki S, Asghari S

doi: 10.1186/s12876-025-03613-8

Related content

Longitudinal response to standard of care in pediatric metabolic dysfunction-associated steatotic liver disease: Rates of improvement and worsening, and factors associated with outcomes

Prevalence of metabolic dysfunction-associated steatotic liver disease and fibrosis defined by liver elastography in the United States using National Health and Nutrition examination survey 2017-march 2020 and august 2021-august 2023 data

Neighborhood social determinants of health are associated with metabolic dysfunction-associated steatotic liver disease outcomes

Metabolic dysfunction-associated steatotic liver disease, metabolic alcohol-related liver disease, and incident dementia: a nationwide cohort study : MASLD, MetALD, and dementia risk

GLP-1 Receptor Agonists and Risk for Cirrhosis and Related Complications in Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease

From "Burnt-Out" to "Burning-Out": Capturing Liver Fat Loss in Patients with Advanced Metabolic Dysfunction-Associated Steatotic Liver Disease from A Dynamic Perspective

Optimal population screening strategies for liver fibrosis associated with metabolic dysfunction-associated steatotic liver disease

Cardiovascular risk assessment tools are insufficient for patients with metabolic dysfunction associated steatotic liver disease

The clinical value of serum sirtuin-1 concentration in the diagnosis of metabolic dysfunction-associated steatotic liver disease